| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-04-27 22:55:19 UTC |
|---|
| Updated at | 2022-04-27 22:55:20 UTC |
|---|
| NP-MRD ID | NP0051619 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | beta-Lapachone |
|---|
| Description | Lapachone, also known as ARQ 501 or beta-lap, belongs to the class of organic compounds known as naphthopyranones. Naphthopyranones are compounds containing a naphthopyran skeleton where a ring carbon bears a carboxylic acid group. Naphthtopyran is made up of the pyran ring fused to a naphthalene ring system. Lapachone is an extremely weak basic (essentially neutral) compound (based on its pKa). beta-Lapachone is found in Catalpa longissima, Haplophragma adenophyllum, Markhamia platycalyx, Markhamia stipulata , Phyllarthron comorense , Tabebuia avellanedae , Tabebuia guayacan and Tectona grandis . beta-Lapachone was first documented in 2006 (PMID: 16822200). Lapachone has been used in trials studying the treatment of Cancer, Carcinoma, Advanced Solid Tumors, Head and Neck Neoplasms, and Carcinoma, Squamous Cell (PMID: 16891723) (PMID: 18180274) (PMID: 18227145) (PMID: 18424157) (PMID: 18706870) (PMID: 19051226). |
|---|
| Structure | CC1(C)CCC2=C(O1)C1=CC=CC=C1C(=O)C2=O InChI=1S/C15H14O3/c1-15(2)8-7-11-13(17)12(16)9-5-3-4-6-10(9)14(11)18-15/h3-6H,7-8H2,1-2H3 |
|---|
| Synonyms | | Value | Source |
|---|
| 3,4-Dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione | ChEBI | | ARQ 501 | ChEBI | | beta-Lap | ChEBI | | b-Lap | Generator | | Β-lap | Generator | | b-Lapachone | Generator | | β-lapachone | Generator |
|
|---|
| Chemical Formula | C15H14O3 |
|---|
| Average Mass | 242.2740 Da |
|---|
| Monoisotopic Mass | 242.09429 Da |
|---|
| IUPAC Name | 2,2-dimethyl-2H,3H,4H,5H,6H-naphtho[1,2-b]pyran-5,6-dione |
|---|
| Traditional Name | β-lapachone |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | CC1(C)CCC2=C(O1)C1=CC=CC=C1C(=O)C2=O |
|---|
| InChI Identifier | InChI=1S/C15H14O3/c1-15(2)8-7-11-13(17)12(16)9-5-3-4-6-10(9)14(11)18-15/h3-6H,7-8H2,1-2H3 |
|---|
| InChI Key | QZPQTZZNNJUOLS-UHFFFAOYSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as naphthopyranones. Naphthopyranones are compounds containing a naphthopyran skeleton where a ring carbon bears a carboxylic acid group. Naphthtopyran is made up of the pyran ring fused to a naphthalene ring system. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Naphthopyrans |
|---|
| Sub Class | Naphthopyranones |
|---|
| Direct Parent | Naphthopyranones |
|---|
| Alternative Parents | |
|---|
| Substituents | - Naphthopyranone
- Naphthoquinone
- Naphthalene
- Quinone
- Aryl ketone
- Benzenoid
- Pyran
- Vinylogous ester
- Ketone
- Oxacycle
- Carbonyl group
- Organooxygen compound
- Hydrocarbon derivative
- Organic oxide
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Woo HJ, Park KY, Rhu CH, Lee WH, Choi BT, Kim GY, Park YM, Choi YH: Beta-lapachone, a quinone isolated from Tabebuia avellanedae, induces apoptosis in HepG2 hepatoma cell line through induction of Bax and activation of caspase. J Med Food. 2006 Summer;9(2):161-8. doi: 10.1089/jmf.2006.9.161. [PubMed:16822200 ]
- Cunha-Filho MS, Landin M, Martinez-Pacheco R, Dacunha-Marinho B: Beta-lapachone. Acta Crystallogr C. 2006 Aug;62(Pt 8):o473-5. doi: 10.1107/S0108270106021706. Epub 2006 Jul 14. [PubMed:16891723 ]
- Miao XS, Song P, Savage RE, Zhong C, Yang RY, Kizer D, Wu H, Volckova E, Ashwell MA, Supko JG, He X, Chan TC: Identification of the in vitro metabolites of 3,4-dihydro-2,2-dimethyl-2H-naphthol[1,2-b]pyran-5,6-dione (ARQ 501; beta-lapachone) in whole blood. Drug Metab Dispos. 2008 Apr;36(4):641-8. doi: 10.1124/dmd.107.018572. Epub 2008 Jan 7. [PubMed:18180274 ]
- Savage RE, Tyler AN, Miao XS, Chan TC: Identification of a novel glucosylsulfate conjugate as a metabolite of 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione (ARQ 501, beta-lapachone) in mammals. Drug Metab Dispos. 2008 Apr;36(4):753-8. doi: 10.1124/dmd.107.018655. Epub 2008 Jan 28. [PubMed:18227145 ]
- Yang RY, Kizer D, Wu H, Volckova E, Miao XS, Ali SM, Tandon M, Savage RE, Chan TC, Ashwell MA: Synthetic methods for the preparation of ARQ 501 (beta-Lapachone) human blood metabolites. Bioorg Med Chem. 2008 May 15;16(10):5635-43. doi: 10.1016/j.bmc.2008.03.073. Epub 2008 Apr 1. [PubMed:18424157 ]
- Savage RE, Hall T, Bresciano K, Bailey J, Starace M, Chan TC: Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ARQ 501 (beta-lapachone) in plasma and tumors from nu/nu mouse xenografts. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep 1;872(1-2):148-53. doi: 10.1016/j.jchromb.2008.07.031. Epub 2008 Jul 31. [PubMed:18706870 ]
- Miao XS, Zhong C, Wang Y, Savage RE, Yang RY, Kizer D, Volckova E, Ashwell MA, Chan TC: In vitro metabolism of beta-lapachone (ARQ 501) in mammalian hepatocytes and cultured human cells. Rapid Commun Mass Spectrom. 2009 Jan;23(1):12-22. doi: 10.1002/rcm.3835. [PubMed:19051226 ]
- Rios-Luci C, Bonifazi EL, Leon LG, Montero JC, Burton G, Pandiella A, Misico RI, Padron JM: beta-Lapachone analogs with enhanced antiproliferative activity. Eur J Med Chem. 2012 Jul;53:264-74. doi: 10.1016/j.ejmech.2012.04.008. Epub 2012 Apr 19. [PubMed:22560628 ]
- Zheng XT, Chen P, Li CM: Anticancer efficacy and subcellular site of action investigated by real-time monitoring of cellular responses to localized drug delivery in single cells. Small. 2012 Sep 10;8(17):2670-4. doi: 10.1002/smll.201102636. Epub 2012 Jun 26. [PubMed:22736525 ]
- Xu J, Wagoner G, Douglas JC, Drew PD: beta-Lapachone ameliorization of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2013 Jan 15;254(1-2):46-54. doi: 10.1016/j.jneuroim.2012.09.004. Epub 2012 Sep 23. [PubMed:23010281 ]
|
|---|